Article Text


260 A Single Centre Retrospective Study of Cytogenetic Profile, Management and Outcome of Acute Myeloid Leukaemia in Children
  1. P O’Hare,
  2. M Taj,
  3. D Lancaster
  1. Paediatric Oncology, Royal Marsden Hospital, London, UK


Background and Aims AML15 was the first major trial to compare anthracycline based consolidation to a Cytosine-Arabinoside based one. Following closure of the trial, standard therapy of cytosine - arabinoside consolidation therapy is currently recommended at this centre. A review of the cytogenetic, treatment and outcome profiles for patients diagnosed with Acute Myeloid Leukaemia was undertaken following concerns regarding relapse rates.

Methods A retrospective study was conducted at the Royal Marsden Hospital on children (aged less than 18), diagnosed to have acute Myeloid Leukaemia between January 2004 and June 2011.

Results A total of 72 patients were identified, of which 7 patients did not achieve remission following induction chemotherapy with ADE. 48 patients were appropriate for comparison, 22 patients received treatment with cytosine - arabinoside (ara-C) based consolidation and 26 patients received treatment with anthracycline based therapy (MACE/MIDAC). 9 patients (41%) in the araC group relapsed and 3 of these patients subsequently died. In only 1 patient this was secondary to resistant disease. Of the 9 patients who relapsed 6 had adverse cytogenetics. Within the group of patients treated with MACE/MIDAC consolidation, 14 relapsed (54%) and of these, 10 patients subsequently died. 6 of the 14 relapsed patients had adverse cytogenetic profiles. No patient within the MACE/MIDAC group had treatment changed due to cardiotoxicity. Chi-squared analysis of death rates identified a p value < 0.1, but more than 0.05.

Conclusions The outcome analysis indicates that there is no significant difference between rates of relapse or death in the 2 groups of patients.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.